We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Burning Rock Biotech Ltd | LSE:BNR | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.35 | 0 | 01:00:00 |
TIDMBNR
RNS Number : 2542W
Blenheim Natural Resources PLC
07 February 2017
7 February 2017
Blenheim Natural Resources Plc
("Blenheim" or the "Company")
Result of General Meeting
Blenheim is pleased to announce that at the Company's General Meeting held earlier today, all resolutions were duly passed.
As a result, shareholders have granted the directors the authority to allot and issue, inter alia, 214,285,714 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") and 214,285,714 warrants over Ordinary Shares, pursuant to the conditional placing announced on 18 January 2017. The directors have also been granted the authority to issue 10,714,286 warrants over Ordinary Shares to Cornhill Capital Limited, the Company's joint broker. Further, shareholders have granted the directors the authority to allot and issue up to 60,000,000 Ordinary Shares as partial consideration, should the Company exercise its option to acquire a 30 per cent interest in the Dieba exploration permit (as announced on 18 January 2017).
The Directors have also been granted authority to buy back and cancel all of the deferred shares in issue for an aggregate consideration of GBP1 at any time prior to 31 December 2017.
Application has been made for the 214,285,714 Ordinary Shares pursuant to the placing, which rank pari passu with the Company's existing issued Ordinary Shares, to be admitted to trading on the AIM Market of the London Stock Exchange ("AIM"). Dealings on AIM are expected to commence at 8:00 a.m. on or around 8 February 2017 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will comprise 398,576,614 Ordinary Shares with voting rights attached (one vote per share). The Company does not hold any shares in treasury. This figure of 398,576,614 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information please contact:
Blenheim Natural +44 (0) 1622 Chris Ells Resources Plc 844601 Colin Aaronson/Jamie Grant Thornton UK Barklem/ Daniel LLP +44 (0) 20 7383 Bush (Nominated Adviser) 5100 SI Capital Ltd (Joint Nick Emerson Broker) +44 (0)1483 413500 Peterhouse Corporate Lucy Williams / Finance Limited (Joint +44 (0) 20 7469 Duncan Vasey Broker) 0932 Cornhill Capital +44 (0) 20 7710 Colin Rowbury Limited (Joint Broker) 9610
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMXDLFBDLFZBBZ
(END) Dow Jones Newswires
February 07, 2017 08:45 ET (13:45 GMT)
1 Year Burning Rock Biotech Chart |
1 Month Burning Rock Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions